Quest Diagnostics Q3 revenue rises 8.5% to $2.49 billion; raises 2024 revenue outlook
Quest Diagnostics reported third-quarter 2024 net revenues of $2.49 billion, up 8.5% from a year earlier, and reported diluted EPS of $1.99, up 1.5%. The company raised its full-year 2024 revenue outlook to $9.80 billion to $9.85 billion, citing recent acquisitions including LifeLabs, while keeping the midpoint of its adjusted EPS outlook unchanged.
Key points
- Q3 2024 net revenues $2.49 billion, up 8.5%; organic growth 4.2% per CEO Jim Davis
- Q3 operating income $330 million, down 3.3% from $342 million; adjusted diluted EPS $2.30, up 3.6%
- 2024 revenue guidance raised to $9.80 billion–$9.85 billion from $9.50 billion–$9.58 billion
- 2024 reported diluted EPS guidance narrowed to $7.60–$7.70; adjusted EPS guidance $8.85–$8.95 from $8.80–$9.00
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.